REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/12/2025
Voltar para busca
Dado oficial do USPTO
EPISCREEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
EPISCREEN
ST13
US500000086716415Classe
5, 42, 44
Pedido
86716415
Registro
5093688
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
07/12/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
06/08/2015
Data de registro
06/12/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/09/2023
Última transação
07/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
704
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
24
Localização do titular
CAMBRIDGE, GB
Examinador
CARROLL,DORITT
Unidade examinadora
M70
Titulares e representantes
Titulares
ABZENA (UK) LIMITED
Polytherics Limited
Representantes
Joyce von Natzmer Agris & von Natzmer LLP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticals and pharmaceutical preparations used to treat cancerdiseases and disorders of the immune systemviral diseases and disordersinflammatory diseasesfibrotic diseasespulmonary diseasesgastro-intestinal diseases and disordershaematological diseases and disordersneurological diseases and disorderspainobesitydiabetes and graft rejection; chemical preparations for medical or pharmaceutical purposeschemicals sold as integral component parts of pharmaceutical preparations for the treatment of cancerdiseases and disorders of the immune systemviral diseases and disordersinflammatory diseasesfibrotic diseasespulmonary diseasesgastro-intestinal diseases and disordershaematological diseases and disordersneurological diseases and disorderspainobesitydiabetes and graft rejection; chemico-pharmaceutical preparationspharmaceutical preparations for the treatment of cancerdiseases and disorders of the immune systemviral diseases and disordersinflammatory diseasesfibrotic diseasespulmonary diseasesgastro-intestinal diseases and disordershaematological diseases and disordersneurological diseases and disorderspainobesitydiabetes and graft rejection; vaccines; pharmaceutical preparations for skin care
Classe 42
Scientific research and product development services in relation to pharmaceutical and medical products; pharmaceutical research services; pharmaceutical product evaluation; testing of pharmaceuticalsassessing the potential immunogenicity of proteins and antibodies by measuring immune cell responses to the pharmaceutical; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of scientific information in the fields of cancerdiseases and disorders of the immune systemviral diseases and disordersinflammatory diseasesfibrotic diseasespulmonary diseasesgastro-intestinal diseases and disordershaematological diseases and disordersneurological diseases and disorderspainobesitydiabetes and graft rejection; toxicology services; provision of scientific information relating to the chemical industryinformation on the subject of chemical product development
Classe 44
Medical servicesproviding medical information regarding pharmaceuticals; Pharmacy and health advice; pharmaceutical services and provision of pharmaceutical informationall in the nature of providing medical information regarding pharmaceuticals; Medical screening; Medical screening to assess the potential immunogenicity of therapeutic antibodies and proteins
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
30/09/2023
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
30/09/2023
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
22/09/2023
PRA8
POST REGISTRATION ACTION MAILED - SEC. 8
02/06/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/06/2023
ES8R
TEAS SECTION 8 RECEIVED
02/12/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/12/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
31/07/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
06/12/2016
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
31/10/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
30/10/2016
IUCN
NOTICE OF ALLOWANCE CANCELLED
11/10/2016
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
11/10/2016
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
23/08/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/06/2016
PUBO
PUBLISHED FOR OPPOSITION
28/06/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/06/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
20/05/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/05/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/05/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/05/2016
ALIE
ASSIGNED TO LIE
28/04/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/04/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/11/2015
GNRT
NON-FINAL ACTION E-MAILED
19/11/2015
CNRT
NON-FINAL ACTION WRITTEN
19/11/2015
DOCK
ASSIGNED TO EXAMINER
18/11/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/08/2015
NWAP
NEW APPLICATION ENTERED
10/08/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EPISCREEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.